Genomic Testing Associated with Improved Survival in Advanced Lung Cancer

A new study published in JNCCN indicates that patients with advanced non-small cell lung cancer (NSCLC) who underwent broad-based genomic sequencing (BGS) before treatment experienced longer overall survival. Analyzing over 35,000 patient records, researchers found BGS was linked to an average two-month increase in survival and modest progression-free survival improvement compared to limited biomarker testing. This suggests BGS helps identify more targets for personalized therapies, aligning with current NCCN Guidelines.